232 related articles for article (PubMed ID: 23921881)
1. The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era.
Mocroft A; Furrer HJ; Miro JM; Reiss P; Mussini C; Kirk O; Abgrall S; Ayayi S; Bartmeyer B; Braun D; Castagna A; d'Arminio Monforte A; Gazzard B; Gutierrez F; Hurtado I; Jansen K; Meyer L; Muñoz P; Obel N; Soler-Palacin P; Papadopoulos A; Raffi F; Ramos JT; Rockstroh JK; Salmon D; Torti C; Warszawski J; de Wit S; Zangerle R; Fabre-Colin C; Kjaer J; Chene G; Grarup J; Lundgren JD;
Clin Infect Dis; 2013 Oct; 57(7):1038-47. PubMed ID: 23921881
[TBL] [Abstract][Full Text] [Related]
2. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
[TBL] [Abstract][Full Text] [Related]
3. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE.
; Young J; Psichogiou M; Meyer L; Ayayi S; Grabar S; Raffi F; Reiss P; Gazzard B; Sharland M; Gutierrez F; Obel N; Kirk O; Miro JM; Furrer H; Castagna A; De Wit S; Muñoz J; Kjaer J; Grarup J; Chêne G; Bucher H
PLoS Med; 2012; 9(3):e1001194. PubMed ID: 22448150
[TBL] [Abstract][Full Text] [Related]
4. AIDS across Europe, 1994-98: the EuroSIDA study.
Mocroft A; Katlama C; Johnson AM; Pradier C; Antunes F; Mulcahy F; Chiesi A; Phillips AN; Kirk O; Lundgren JD
Lancet; 2000 Jul; 356(9226):291-6. PubMed ID: 11071184
[TBL] [Abstract][Full Text] [Related]
5. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata.
Reekie J; Gatell JM; Yust I; Bakowska E; Rakhmanova A; Losso M; Krasnov M; Francioli P; Kowalska JD; Mocroft A;
AIDS; 2011 Nov; 25(18):2259-68. PubMed ID: 21918422
[TBL] [Abstract][Full Text] [Related]
6. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.
; Lodwick RK; Sabin CA; Porter K; Ledergerber B; van Sighem A; Cozzi-Lepri A; Khaykin P; Mocroft A; Jacobson L; De Wit S; Obel N; Castagna A; Wasmuth JC; Gill J; Klein MB; Gange S; Riera M; Mussini C; Gutiérrez F; Touloumi G; Carrieri P; Guest JL; Brockmeyer NH; Phillips AN
Lancet; 2010 Jul; 376(9738):340-5. PubMed ID: 20638118
[TBL] [Abstract][Full Text] [Related]
7. Course and Clinical Significance of CD8+ T-Cell Counts in a Large Cohort of HIV-Infected Individuals.
Helleberg M; Kronborg G; Ullum H; Ryder LP; Obel N; Gerstoft J
J Infect Dis; 2015 Jun; 211(11):1726-34. PubMed ID: 25489001
[TBL] [Abstract][Full Text] [Related]
8. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL.
Atkinson A; Miro JM; Mocroft A; Reiss P; Kirk O; Morlat P; Ghosn J; Stephan C; Mussini C; Antoniadou A; Doerholt K; Girardi E; De Wit S; Kraus D; Zwahlen M; Furrer H;
J Int AIDS Soc; 2021 Jun; 24(6):e25726. PubMed ID: 34118121
[TBL] [Abstract][Full Text] [Related]
9. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.
Mocroft A; Phillips AN; Gatell J; Ledergerber B; Fisher M; Clumeck N; Losso M; Lazzarin A; Fatkenheuer G; Lundgren JD;
Lancet; 2007 Aug; 370(9585):407-13. PubMed ID: 17659333
[TBL] [Abstract][Full Text] [Related]
10. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
11. Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years.
Davy-Mendez T; Napravnik S; Eron JJ; Cole SR; van Duin D; Wohl DA; Hogan BC; Althoff KN; Gebo KA; Moore RD; Silverberg MJ; Horberg MA; Gill MJ; Mathews WC; Klein MB; Colasanti JA; Sterling TR; Mayor AM; Rebeiro PF; Buchacz K; Li J; Nanditha NGA; Thorne JE; Nijhawan A; Berry SA;
J Infect Dis; 2021 Aug; 224(4):657-666. PubMed ID: 34398239
[TBL] [Abstract][Full Text] [Related]
12. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
[TBL] [Abstract][Full Text] [Related]
13. Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database.
Rajasuriar R; Gouillou M; Spelman T; Read T; Hoy J; Law M; Cameron PU; Petoumenos K; Lewin SR
PLoS One; 2011; 6(6):e20713. PubMed ID: 21674057
[TBL] [Abstract][Full Text] [Related]
14. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
15. CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use.
Mocroft A; Phillips AN; Gatell J; Horban A; Ledergerber B; Zilmer K; Jevtovic D; Maltez F; Podlekareva D; Lundgren JD;
AIDS; 2013 Mar; 27(6):907-918. PubMed ID: 23698060
[TBL] [Abstract][Full Text] [Related]
16. Utility of CD4 count measurement in the era of universal antiretroviral therapy: an analysis of routine laboratory data in Botswana.
Leeme TB; Mine M; Lechiile K; Mulenga F; Mosepele M; Mphoyakgosi T; Muthoga C; Ngidi J; Nkomo B; Ramaabya D; Tau M; Tenforde MW; Hayes R; Jarvis JN
HIV Med; 2021 Jan; 22(1):1-10. PubMed ID: 32876378
[TBL] [Abstract][Full Text] [Related]
17. Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort.
De Beaudrap P; Etard JF; Diouf A; Ndiaye I; Ndèye GF; Sow PS; Ndèye KC; Ecochard R; Delaporte E;
BMC Infect Dis; 2010 Jun; 10():179. PubMed ID: 20565900
[TBL] [Abstract][Full Text] [Related]
18. Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes.
; Costagliola D; Ledergerber B; Torti C; van Sighem A; Podzamczer D; Mocroft A; Dorrucci M; Masquelier B; de Luca A; Jansen K; De Wit S; Obel N; Fätkenheuer G; Touloumi G; Mussini C; Castagna A; Stephan C; García F; Zangerle R; Duval X; Perez-Hoyos S; Meyer L; Ghosn J; Fabre-Colin C; Kjaer J; Chêne G; Grarup J; Phillips A; Lodwick R; Torti C; Dorrucci M; Günthard HF; Michalik C; Chrysos G; Castagna A
J Infect Dis; 2013 Mar; 207(5):759-67. PubMed ID: 23225900
[TBL] [Abstract][Full Text] [Related]
19. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.
Guiguet M; Boué F; Cadranel J; Lang JM; Rosenthal E; Costagliola D;
Lancet Oncol; 2009 Dec; 10(12):1152-9. PubMed ID: 19818686
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
